Spots Global Cancer Trial Database for oesophageal squamous cell carcinoma
Every month we try and update this database with for oesophageal squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | NCT05104567 | Oesophageal Squ... Gastric Cancer Hepatocellular ... Colorectal Canc... Oesophageal Ade... | THOR-707 Pembrolizumab Cetuximab | 18 Years - | Sanofi | |
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | NCT05104567 | Oesophageal Squ... Gastric Cancer Hepatocellular ... Colorectal Canc... Oesophageal Ade... | THOR-707 Pembrolizumab Cetuximab | 18 Years - | Sanofi | |
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma | NCT04215471 | Oesophageal Squ... | PD-L1 Antibody ... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | NCT05104567 | Oesophageal Squ... Gastric Cancer Hepatocellular ... Colorectal Canc... Oesophageal Ade... | THOR-707 Pembrolizumab Cetuximab | 18 Years - | Sanofi | |
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | NCT02735239 | Esophageal Canc... | Durvalumab Tremelimumab Oxaliplatin Capecitabine Radiotherapy Paclitaxel Carboplatin 5-fluorouracil ... Leucovorin Docetaxel | 18 Years - | Ludwig Institute for Cancer Research |